SUB-Q sub-estimate
This article was originally published in The Gray Sheet
Executive Summary
QuickSeal vascular sealing device maker earns FDA approval based on a 398-patient trial, not 39 patients, as previously reported ("1The Gray Sheet" April 29, 2002, p. 19)...
You may also be interested in...
SUB-Q QuickSeal Closes Hole In Boston Scientific Endovascular Line
Boston Scientific will enter the rapidly expanding vascular access closure device market in May through the distribution of SUB-Q's QuickSeal vascular sealing device, under a licensing and equity agreement announced April 23. The QuickSeal earned PMA approval on March 25
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.